German clinical-stage biotech company Innovative Molecules GmbH announced on Thursday announced the successful completion of its Phase 1 clinical development programme and the transition into Phase 2 for its oral selective helicase primase HSV inhibitor adibelivir (IM-250).

The Phase 1 clinical development programme included: a Phase 1a single-ascending dose study in healthy volunteers; a multiple-ascending dose study in healthy volunteers; a food-effect study in healthy volunteers; and the Phase 1b part of the combined Phase 1b/2a study in patients with genital herpes.

Across these studies, oral adibelivir demonstrated a clinical profile that supports advancement into the Phase 2a, efficacy-focused part of the IM-202 trial, Innovative Molecules said.